DISEASE-SPECIFIC CANCER CONTROL
90 CANCER CONTROL 2014
References
1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human
papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
2. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human
papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role
of duration of infection. JNCI Cancer Spectrum. 2010;102(5):315-324.
3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology
of human cancer. Vaccine. 2006;24(3):S1-S10.
4. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical
cytology screening. Vaccine. 2006;24 Suppl 3:S3/63-70.
5. Nene BM, Deshpande S, Jayant K, et al. Early detection of cervical cancer by visual
inspection: a population-based study in rural India. Int J Cancer. 1996;68(6):770-773.
6. PATH. Course in Visual Methods for Cervical Cancer Screening: Visual Inspection with
Acetic Acid and Lugol's Iodine. Seattle: PATH; 2004.
7. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus
Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-
1588.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for
the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a
randomised controlled trial. Lancet Oncol. 2010;11(3):249-257.
9. Cuzick J, Bergeron C, von Knebel DM, et al. New technologies and procedures for
cervical cancer screening. Vaccine. 2012;30 Suppl 5:F107-F116.
10. Sancho-Garnier H, Tamalet C, Halfon P, et al. HPV self-sampling or the Pap-smear: a
randomized study among cervical screening nonattenders from lower socioeconomic
groups in France. Int J Cancer. 2013;133(11):2681-2687.
11. Ogilvie GS, Mitchell S, Sekikubo M, et al. Results of a community-based cervical cancer
screening pilot project using human papillomavirus self-sampling in Kampala, Uganda.
Int J Gynaecol Obstet. 2013;122(2):118-123.
12. World Health Organization (WHO). A Draft Comprehensive Global Monitoring
Framework, including Indicators, and a Set of Voluntary Global Targets for the
Prevention and Control of Noncommunicable Diseases. A/NCD/INF/1. Geneva: WHO;
2012. Available at: http://apps.who.int/gb/ncds/pdf/a_ncd_inf1-en.pdf. Accessed
December 6, 2013.
13. Tsu VD, Jeronimo J, Anderson BO. Why the time is right to tackle breast and cervical
cancer in low-resource settings. Bull World Health Organ. 2013;91(9):683-690.
14. Sherris J, Wittet S, Kleine A, et al. Evidence-based, alternative cervical cancer
screening approaches in low-resource settings. Int Perspect Sex Reprod Health.
2009;35(3):147-154.
15. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical
cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet.
2007;370(9585):398-406.
16. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in
rural India. N Engl J Med. 2009;360(14):1385-1394.
17. WHO. WHO Guidelines for Screening and Treatment of Precancerous Lesions for
Cervical Cancer Prevention. Geneva: WHO; 2013. Available at:
http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatmen
t_of_precancerous_lesions/en/index.html. Accessed December 6, 2013.
18. Cervical Cancer Action. Global Maps. 2013. Available at:
http://www.cervicalcanceraction.org/comments/comments.php. Accessed December
6, 2013.
19. WHO, Pan American Health Organization (PAHO). Monitoring National Cervical
Cancer Prevention and Control Programmes: Quality Control and Quality Assurance
for Visual Inspection with Acetic Acid (VIA)-Based Programmes. Geneva: WHO; 2013.
20. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K. Safety, acceptability, and
feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a
demonstration project. Lancet. 2003;361(9360):814-820.
21. de Cristofaro D, Fontana P, Pezzoli C. Pathologic study of the cervix after cold
coagulation. Am J Obstet Gynecol. 1988;159(5):1053-1054.
22. Haddad N, Hussein I, Blessing K, Kerr-Wilson R, Smart G. Tissue destruction following
cold coagulation of the cervix. Journal of Gynecologic Surgery. 1988;4(1):23-27.
23. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer
and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible
utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst.
2005;97(14):1072-1079.
24. Muwonge R, Wesley RS, Nene BM, et al. Evaluation of cytology and visual triage of
human papillomavirus-positive women in cervical cancer prevention in India. Int J
Cancer. 2013. Epub ahead of print. Available at:
http://onlinelibrary.wiley.com/doi/10.1002/ijc.28627/pdf. Accessed December 6, 2013.
25. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a
population-based HPV vaccination program on cervical abnormalities: a data linkage
study. BMC Med. 2013;11(1):227.
26. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination
on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine.
2012;31(1):109-113.
27. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human
papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis.
2012;12(10):781-789.
28. Van d, V, Boily MC, Drolet M, et al. Population-level impact of the bivalent,
quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
J Natl Cancer Inst. 2012;104(22):1712-1723.